Antineoplastics
1
Reactions 1228 - 15 Nov 2008 of LRP expression in bone marrow cells after chemotherapy and might deteriorate the outcome of these [multiple S Antineoplastics myeloma] patients. . . In summary, integrin β1 and LRP might confer chemotherapy-resistant character to [multiple Overexpression of integrin-β1, and drug resistance: myeloma] cells." 17 case reports In a study investigating the effects of chemotherapy on Kurata M, et al. Induction of integrin beta 1 expression in bone marrow cells after expression of integrin β1, lung resistance protein (LRP) and chemotherapy correlates with the overexpression of lung resistance protein and poor outcome in patients with multiple myeloma. American Journal of Hematology multidrug resistance (MDR) genes in multiple myeloma, 83: 755-757, No. 9, Sep 2008 - Japan 801124542 17 patients were identified in whom overexpression of integrin β1 was observed. This correlated with overexpression of LRP and a poor survival outcome. Patient treatment and survival Patient/sex/ Treatment regimen Survival age (y) (m) 1/M/44 MP x 3, MCNU-VMP x 5, VAD x 1 13 2/F/85 MCNU-VMP x 9 18 3/F/66 MP x 3, VAD x 6, MCNU-VMP x 8, 20 HD a -CPM/VP-16, HD-L-PAM + PBSCT 4/F/63 MP x 7, IFN x 1, MCNU-VMP x 3, 24 VAD x 1, HD-CPM/VP-16 x 1, ICE + PBSCT 5/M/71 IFN x 1, MCNU-VMP x 7, VAD x 2, 31 HD-Dex b x 2 6/F/74 MP x 8, IFN x 1, MCNU-VMP x 5, 35 VAD x 1 7/F/78 MP x 2, MCNU-VMP x 1, VAD x 6 36 8/M/54 MP x 2, IFN x 2, MCNU-VMP x 3, 40 VAD x 6, HD-CPM/VP-16 x 1, auto- PBSCT 9/F/46 MCNU-VMP x 4, VAD x 1, HD- 43 CPM/VP-16 x 1 10/F/69 MCNU-VMP x 4, MP x 16, VAD x 3, 48 HD-CPM/VP-16 11/F/66 MCNU-VMP x 3, IFN x 2, HD-CPM/ 48 VP-16, MCNU-VMP 12/M/56 MCNU-VMP x 3, HD-CPM/VP-16, 48 MP x 9 13/M/71 MCNU-VMP x 4, VAD x 4, IFN, HD- >60 CPM/VP-16 x 1 14/M/70 MP x 1, IFN x 1, MCNU-VMP x 2 >60 15/M/75 MCNU-VMP x 4, IFN, MCNU-VMP >60 x 2, HD-CMP/VP-16, MP x 2, MCNU-VMD x 2 16/F/71 MP x 1, IFN x 1, MCNU-VMP x 2, >60 VAD x 8, HD-CPM/VP-16 x 1 17/M/50 MCNU-VMP x 3, IFN x 5, >60 HD-CMP/VP-16 a high-dose, b dexamethasone The nine women and eight men aged 44–85 years received a variety of antineoplastics [dosages not stated] in the following regimens [see table]: melphalan and prednisolone (MP), ranimustine (MCNU), vincristine, melphalan, prednisolone (VMP), vincristine, adriamycin, dexamethasone (VAD), cyclophosphamide (CPM), etoposide (VP-16), melphalan (L- PAM), interferon (IFN) and/or ifosphamide, carboplatin, etoposide (ICE). Patients 3, 4 and 8 also underwent peripheral blood stem cell transplantation (PBSCT). Expression levels of integrin β1 by bone marrow cells were determined both pre- and post-chemotherapy. Levels of LRP and MDR1 were also measured. There was a positive, significant correlation between integrin β1 expression and LRP expression [duration of therapies to reaction onset not stated]. The patients with chemotherapy-induced overexpression of integrin β1 subsequently had a significantly shorter survival time than patients without an overexpression of integrin β1. Author comment: "These findings suggest that the chemotherapy-induced overexpression of integrin β1 in a part of [multiple myeloma] patients would cause the upregulation 1 Reactions 15 Nov 2008 No. 1228 0114-9954/10/1228-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 1228 - 15 Nov 2008
of LRP expression in bone marrow cells after chemotherapyand might deteriorate the outcome of these [multiple SAntineoplastics myeloma] patients. . . In summary, integrin β1 and LRP mightconfer chemotherapy-resistant character to [multipleOverexpression of integrin-β1, and drug resistance:myeloma] cells."17 case reports
In a study investigating the effects of chemotherapy on Kurata M, et al. Induction of integrin beta 1 expression in bone marrow cells afterexpression of integrin β1, lung resistance protein (LRP) and chemotherapy correlates with the overexpression of lung resistance protein and
poor outcome in patients with multiple myeloma. American Journal of Hematologymultidrug resistance (MDR) genes in multiple myeloma,83: 755-757, No. 9, Sep 2008 - Japan 80112454217 patients were identified in whom overexpression of
integrin β1 was observed. This correlated withoverexpression of LRP and a poor survival outcome.
Patient treatment and survivalPatient/sex/ Treatment regimen Survivalage (y) (m)
1/M/44 MP x 3, MCNU-VMP x 5, VAD x 1 132/F/85 MCNU-VMP x 9 183/F/66 MP x 3, VAD x 6, MCNU-VMP x 8, 20
HDa -CPM/VP-16, HD-L-PAM + PBSCT
4/F/63 MP x 7, IFN x 1, MCNU-VMP x 3, 24VAD x 1, HD-CPM/VP-16 x 1,
ICE + PBSCT5/M/71 IFN x 1, MCNU-VMP x 7, VAD x 2, 31
HD-Dexb x 26/F/74 MP x 8, IFN x 1, MCNU-VMP x 5, 35
VAD x 17/F/78 MP x 2, MCNU-VMP x 1, VAD x 6 368/M/54 MP x 2, IFN x 2, MCNU-VMP x 3, 40
VAD x 6, HD-CPM/VP-16 x 1, auto-PBSCT
9/F/46 MCNU-VMP x 4, VAD x 1, HD- 43CPM/VP-16 x 1
10/F/69 MCNU-VMP x 4, MP x 16, VAD x 3, 48HD-CPM/VP-16
11/F/66 MCNU-VMP x 3, IFN x 2, HD-CPM/ 48VP-16, MCNU-VMP
12/M/56 MCNU-VMP x 3, HD-CPM/VP-16, 48MP x 9
13/M/71 MCNU-VMP x 4, VAD x 4, IFN, HD- >60CPM/VP-16 x 1
14/M/70 MP x 1, IFN x 1, MCNU-VMP x 2 >6015/M/75 MCNU-VMP x 4, IFN, MCNU-VMP >60
x 2, HD-CMP/VP-16, MP x 2,MCNU-VMD x 2
16/F/71 MP x 1, IFN x 1, MCNU-VMP x 2, >60VAD x 8, HD-CPM/VP-16 x 1
17/M/50 MCNU-VMP x 3, IFN x 5, >60 HD-CMP/VP-16
a high-dose, b dexamethasone
The nine women and eight men aged 44–85 years received avariety of antineoplastics [dosages not stated] in the followingregimens [see table]: melphalan and prednisolone (MP),ranimustine (MCNU), vincristine, melphalan, prednisolone(VMP), vincristine, adriamycin, dexamethasone (VAD),cyclophosphamide (CPM), etoposide (VP-16), melphalan (L-PAM), interferon (IFN) and/or ifosphamide, carboplatin,etoposide (ICE). Patients 3, 4 and 8 also underwent peripheralblood stem cell transplantation (PBSCT). Expression levels ofintegrin β1 by bone marrow cells were determined both pre-and post-chemotherapy. Levels of LRP and MDR1 were alsomeasured.
There was a positive, significant correlation betweenintegrin β1 expression and LRP expression [duration oftherapies to reaction onset not stated]. The patients withchemotherapy-induced overexpression of integrin β1subsequently had a significantly shorter survival time thanpatients without an overexpression of integrin β1.
Author comment: "These findings suggest that thechemotherapy-induced overexpression of integrin β1 in a partof [multiple myeloma] patients would cause the upregulation
1
Reactions 15 Nov 2008 No. 12280114-9954/10/1228-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
